Non-Current Assets

Operating Lease Right-of-Use Assets in Other Assets

West Pharmaceutical Services Operating Lease Right-of-Use Assets in Other Assets decreased by 5.8% to $110.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.6%, from $103.40M to $110.20M. Over 5 years (FY 2020 to FY 2025), Operating Lease Right-of-Use Assets in Other Assets shows an upward trend with a 11.4% CAGR.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Assets
First reportedQ4 2018
Last reportedQ1 2026
Metric ID: operating_lease_rou_assets_in_other

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$62.80M$58.50M$69.30M$75.60M$76.90M$86.60M$104.40M$101.10M$99.20M$96.80M$99.20M$96.80M$110.30M$108.00M$104.50M$103.40M$104.40M$97.80M$117.00M$110.20M
QoQ Change-6.8%+18.5%+9.1%+1.7%+12.6%+20.6%-3.2%-1.9%-2.4%+2.5%-2.4%+13.9%-2.1%-3.2%-1.1%+1.0%-6.3%+19.6%-5.8%
YoY Change+22.5%+48.0%+50.6%+33.7%+29.0%+11.8%-5.0%-4.3%+11.2%+11.6%+5.3%+6.8%-5.3%-9.4%+12.0%+6.6%
Range$58.50M$117.00M
CAGR+12.6%
Avg YoY Growth+14.1%
Median YoY Growth+11.4%

Operating Lease Right-of-Use Assets in Other Assets at Other Companies

Frequently Asked Questions

What is West Pharmaceutical Services's operating lease right-of-use assets in other assets?
West Pharmaceutical Services (WST) reported operating lease right-of-use assets in other assets of $110.20M in Q1 2026.
How has West Pharmaceutical Services's operating lease right-of-use assets in other assets changed year-over-year?
West Pharmaceutical Services's operating lease right-of-use assets in other assets increased by 6.6% year-over-year, from $103.40M to $110.20M.
What is the long-term trend for West Pharmaceutical Services's operating lease right-of-use assets in other assets?
Over 5 years (2020 to 2025), West Pharmaceutical Services's operating lease right-of-use assets in other assets has grown at a 11.4% compound annual growth rate (CAGR), from $68.30M to $117.00M.